Fungal Infections

Six hundred thirty-seven cases in England, 4514 US clinical cases in 2023, and only 3 late‑stage antifungal drugs reveal surveillance and treatment gaps.

Jane E. Sykes, BVSc (Hons), PhD, MPH, MBA, discussed how her study revealed a wider geographic distribution of valley fever, highlighting the need for improved human surveillance.

Study uncovers the role of ploidy plasticity in fungal adaptation to fungicides, highlighting risks for human health and agricultural systems.

Sharmeen Roy, PharmD, BCPS, discusses the role of Bayesian dosing, therapeutic drug monitoring, and hospital resource allocation.

Ashraf S. Ibrahim, PhD, outlines safety studies and the potential of this antibody therapy for treating this rare fungal infection, which is seemingly becoming less rare.

The organization's reports discuss the small number of newly approved treatments, the limited, late-stage antifungal pipeline, and challenges around diagnostics for this class of infections.

This week, the FDA approved two new drugs, gepotidacin for treating uUTIs in females aged 12 and older, and Tesamorelin F8 for managing excess abdominal fat in adults with HIV-associated lipodystrophy.

This week, recent studies include Mandimycin for resistant fungal infections, fluctuating hospital AMR rates, a 6-month HIV treatment, global challenges in hepatitis testing, and the start of a Lassa fever vaccine trial.

Examined over a 5-year period, the Jackson Health System in Florida reported large volumes of positive cultures for the fungal infection every year and that infection sources expanded over time.

Zhuo Shang, PhD’s discovery of mandimycin offers a potential solution to drug-resistant infections like Candida auris by targeting phospholipids in fungal membranes.

Emblaveo for multidrug-resistant infections, advancing RNA therapies and new vaccine options, Vaxart's oral norovirus vaccine, and synthetic gel for ABSSSI, and more.

This is the second installment of a 2-part report on a new guideline on candidiasis from the European Confederation for Medical Mycology (ECMM) highlights selected treatment recommendations.

This first of a 2-part report on new guideline from the European Confederation for Medical Mycology (ECMM) summarizes diagnostic considerations; with part 2 describing recommended treatments.

This week, the FDA set a target date for lenacapavir’s approval, as rising cases of dengue, measles, and other emerging threats continue to spread, alongside a dairy worker transmitting avian flu to his cats.

The fixed-dose combination will be used outside the EU to treat soil-transmitted helminths and lymphatic filariasis.

Oliver A Cornely shares guidance on tackling Candida infections in an evolving landscape, including rising resistance and taxonomic changes.

Koos Korsten, MD, PhD, MSc discusses how clinical context, including prevalence and outbreak situations, influences the choice between PCR and culture-based diagnostics for Candidozyma auris.

This week, five all-oral TB regimens showed efficacy, fungal biofilm diseases remain challenging, over 2 million pastries were recalled due to contamination, and more.

Carlien Pohl-Albertyn's, PhD research highlights the role of the South African brown locust in the transmission and survival of the emerging pathogen Candida auris.

Targeted therapies represent a promising evolution in infectious disease treatment, offering precision approaches to combat resistant pathogens while addressing key limitations in traditional broad-spectrum treatments.

Kirsten Nielsen, PhD, discusses how her team’s research could lead to better understanding and treatment of cryptococcal meningitis.

European agencies warn that non-medical fungicide use may be fueling resistance in A fumigatus, a mold responsible for severe human infections.

Children with invasive candidiasis had successful outcome whether IV antifungal treatment was completed or converted to enteral to reduce risk of infusion site infections and costs.

Kansas is experiencing the largest tuberculosis outbreak in decades, a preview into vaccines and treatments up for FDA approval this winter/spring, and more.

Alejandro Krolewiecki, MD discusses the path to regulatory approval, collaboration with global health organizations, and the role of partnerships in scaling up the new treatment for neglected tropical diseases.